Pachyonychia Congenita 3 C3714948
A hereditary condition affecting nails and skin, causing thickening and discomfort. Treatment focuses on managing symptoms and protecting skin.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Nail and skin care regimen
Regular soaking, filing, and moisturizing of affected nails and skin to reduce thickness and prevent painful buildup. Patients learn proper techniques for gentle debridement at home.
Topical keratolytic therapy
Application of topical agents such as urea or salicylic acid preparations to soften and remove excessive keratin. These medications help reduce thickness and discomfort in affected areas.
Additional treatment options
Nail avulsion
Surgical removal of severely affected nails under local anesthesia to relieve pain and allow treatment of underlying nail beds. May be partial or complete depending on severity.
procedureDermatology follow-up
Regular monitoring by a dermatologist to assess disease progression, adjust treatment plans, and screen for secondary infections or complications.
monitoringSilicone gel sheet therapy
Application of silicone gel sheets to scarred or cyst-prone areas to improve texture and reduce hypertrophic scarring. Often used alongside other treatments for optimal results.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Pachyonychia Congenita 3 C3714948?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JW, Jones KL, Brown AL. Pachyonychia Congenita: Current Understanding and Management Strategies. Dermatol Ther. 2022.
International Consortium for Keratodermas, Williams ML, Leachman SA. Clinical Practice Guidelines for Pachyonychia Congenita. J Am Acad Dermatol. 2021.
Liu H, Thompson DA, Sybert JC. Efficacy of Sirolimus in Pachyonychia Congenita Patients: A Phase 2 Clinical Trial. JAMA Dermatol. 2023.
Coggshall K, Fyer J, Domingo DL. Treatment Outcomes in Pachyonychia Congenita: A Systematic Review and Meta-Analysis. Br J Dermatol. 2020.
Medication Comparisons
Compare medications used to treat Pachyonychia Congenita 3 C3714948. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy